Context. Healthcare worker exposure to antineoplastic drugs continues to be reported despite safe handling guidelines published by several groups. Sensitive sampling and analytical methods are needed so that occupational safety and health professionals may accurately assess environmental and biological exposure to these drugs in the workplace.
Objective. To develop liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) analytical methods for measuring five antineoplastic drugs in samples from the work environment, and to apply these methods in validating sampling methodology. A single method for quantifying several widely used agents would decrease the number of samples required for method development, lower cost, and time of analysis. Methods for measuring these drugs in workers’ urine would also be useful in monitoring personal exposure levels.
Results. LC-MS/MS methods were developed for individual analysis of five antineoplastic drugs in wipe and air sample media projected for use in field sampling: cyclophosphamide, ifosfamide, paclitaxel, doxorubicin, and 5-fluorouracil. Cyclophosphamide, ifosfamide, and paclitaxel were also measured simultaneously in some stages of the work. Extraction methods for air and wipe samples were developed and tested using the aforementioned analytical methods. Good recoveries from the candidate air and wipe sample media for most of the compounds, and variable recoveries for test wipe samples depending on the surface under study, were observed. Alternate LC-MS/MS methods were also developed to detect cyclophosphamide and paclitaxel in urine samples.
Conclusions. The sampling and analytical methods were suitable for determining worker exposure to antineoplastics via surface and breathing zone contamination in projected surveys of healthcare settings.
ConnorTHMcDiarmidMA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin2006; 56: 354–365.
2.
NIOSH Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. DHHS (NIOSH) Pub No. 2004-165, September 2004.
3.
FalckKGröhnPSorsaMVainioHHeinonenEHolstiLR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet1979; 1: 1250–1251.
4.
OSHA. Guidelines for cytotoxic (antineoplastic) drugs. Publication No. 8-1.1, January 1986.
5.
OSHA Directorate of Technical Support. Controlling occupational exposure to hazardous drugs. Instruction TED 1.15, September 1995.
6.
OSHA Directorate of Technical Support. Controlling occupational exposure to hazardous drugs. Instruction TED 1.15, January 1999.
7.
ConnorTHAndersonRWSessinkPJMBroadfieldLPowerLA. Surface contamination with antineoplastic agents in six cancer treatment centers in the United Sates and Canada. Am J Health Syst Pharm1999; 56: 1427–1432.
8.
SottaniCRinaldiPLeoniE. Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation. Rapid Commun Mass Spectrom2008; 22: 2645–2659.
9.
MasonHJBlairSSamsC. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg2005; 49: 603–610.
10.
SottaniCTranfoGBettinelliMFarrandaPSpagnoliMMinoiaC. Trace determination of anthracyclines in urine: a new high-performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel. Rapid Commun Mass Spectrom2004; 18: 2426–2436.
11.
FavierBGillesLGesageMLatourJF. Analysis of cyclophosphamide in the urine of antineoplastic drug handlers. Bull Cancer2003; 90: 905–909.
12.
PethranASchierlRHauffKGrimmC-HBoosK-SNowakD. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health2003; 76: 5–10.
13.
WickCSlawsonMHJorgensonJATylerLS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm2003; 60: 2314–2320.
14.
NymanHJorgensonJSlawsonMH. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm2007; 42: 219–225.
15.
TurciRSottaniCRonchiAMinoiaC. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett2002; 134: 57–64.
16.
World Health Organization. ‘Are the number of cancer cases increasing or decreasing? 2008; Cancer: WHO cancer control programme’, Online Referencing,http://www.who.int/features/qa/15/en/index.html (accessed February 2010).
17.
AbelEA. Immunosuppressant and cytotoxic drugs: unapproved uses or indications. Clin Dermatol2000; 18: 95–101.
18.
LucroyMD. Chemotherapy safety in veterinary practice: hazardous drug preparation. Comp Cont Educ Pract Vet2001; 24: 140–146.
19.
ConnorTHSessinkPJMHarrisonBR. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm2005; 62: 475–484.
20.
ZeedijkMGreidjanusBSteenstraFBUgesDRA. Monitoring exposure of cytostatics on the hospital ward: measuring surface contamination of four different cytostatic drugs from one wipe sample. Eur J Hosp Pharm Sci2005; 11: 18–22.
21.
MinoiaCTurciRSottaniC. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom1998; 12: 1485–1493.
22.
TurciRSottaniCSpagnoliGMinoiaC. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci2003; 789: 169–209.
23.
SabatiniLBarbieriATosiMViolanteFS. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom2005; 40: 669–674.
24.
SottaniCTurciRSchierlR. Simultaneous determination of gemcitabine, taxol, cyclophosphamide and ifosfamide in wipe samples by high-performance liquid chromatography/tandem mass spectrometry: protocol of validation and uncertainty of measurement. Rapid Commun Mass Spectrom2007; 21: 1289–1296.
25.
FransmanWHuizerDTuerkJKromhautH. Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility. Int Arch Occup Environ Health2007; 80: 396–403.
26.
De JongeMEVan DamSMHillebrandMJXRosingHHultemaADRRodenhulsS. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N, N’,N’’-triethylenethiophosphoramide and N, N’,N”-triethylenephosphoramide in human plasma by high-perfomance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom2004; 39: 262–271.
27.
LarsonRRKhazaeliMBDillonHK. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm2002; 59: 270–277.
28.
LarsonRRKhazaeliMBDillonHK. Development of an HPLC method for simultaneous analysis of five antineoplastic agents. Appl Occup Environ Hyg2003; 18: 109–119.
29.
ConnorTHDeBordDGPrettyJRRogersBEscalanteCPLeesPSJ. Evaluation of antineoplastic drug exposure of healthcare workers at three university-based U.S. cancer centers. J Occup Exp Monitoring2010; 52: 1019–1027.
30.
LarsonRRKhazaeliMBDillonHK. A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occup Environ Hyg2003b; 18: 120–131.
31.
SchmausGSchierlRFunckS. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm2002; 59: 956–956.
32.
HedmerMJonssonBAGNygrenO. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. J Environ Monit2004; 6: 979–984.
